Business Wire

CA-HAI-ROBOTICS

22.3.2022 11:44:04 CET | Business Wire | Press release

Share
HAI ROBOTICS to Debut Cutting-edge ACR Systems in U.S. at MODEX 2022

HAI ROBOTICS , the pioneer in Autonomous Case-handling Robot (ACR) systems for warehouse logistics, will present its highly flexible totes-to-person warehouse automation solution at this year’s MODEX 2022 show, Booth C4585 at Georgia World Congress Center in Atlanta from March 28th to 31st.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005613/en/

With its robots being exhibited also by MHS, SVT Robotics, GreyOrange and Tompkins Robotics, the company will demonstrate alongside its strategic partners how its state-of-the-art warehousing technology complements the global supply chain.

Days ahead of MODEX 2022, HAI ROBOTICS announced new partnerships with Tompkins Robotics and Storage Solutions. The partnerships will see technology and solutions developed by HAI ROBOTICS being applied to various industries across North America.

Brian Reinhart, Vice President of Sales and Marketing at HAI ROBOTICS U.S., said the company would have a full display of its commitment to customers, partners and the U.S. market at the show after being in the market for over a year.

"It's a very exciting time for HAI ROBOTICS as we continue our expansion and growth in the U.S." he said. "In order to best serve the market and accommodate the requests of our end users, we are developing a robust, strong, and valuable partner network."

Reinhart, a veteran in the material-handling industry, says: "In a short time, we have planted deep roots in the U.S."

In addition to existing customers and partners, HAI ROBOTICS has established a U.S. HQ in Fremont, CA, a fully functional Demo Center with a decentralized sales and implementation strategy, positioning employees in 15 different states across the country.

The company's "ambitious goals have hiring, onboarding, and training of talented individuals as a top priority." "We want to be where our customers are to best serve them. We are committed to providing our partners with the best industry products, solutions, and service," he said.

Exhibits

The company's exhibits this year include two types of ACR robots and one workstation that were crafted to explore the full potentials of order-fulfillment efficiency, deployment flexibility and scalability in a goods-to-person order-handling context.

The HAIPICK A42T robot to be displayed is an evolution of the company’s IFOY 2021 "Best in Intralogistics" title earner. With a telescopic lift function that can flexibly adjust its picking height, it can handle bins (totes or cartons) at a storage height ranging from 0.28 to 10 meters.

It can carry 8 loads to feed goods-to-person workstations in one move, and shuttle between different storage areas without hindrance.

The HAIPICK A3 fork-lifting robot is a new invention that targets wider warehousing scenarios in addition to bin storage. It handles goods that don’t require a container, such as tires, trays and boards that can be lifted by a fork from the bottom. Its fork-lifting design brings an extra benefit of higher storage density, since spaces between neighboring bins can be reduced. This type of robot is a good match with working environments where control for dust, static and pollution is strict.

In addition to high flexibility, the HAIPICK robots outperform other goods-transporting robots by bringing every inch under the ceiling available for storage. However, it is the teamwork with the HAIPORT-powered Workstation that maximizes a warehouse’s throughput capacity.

A HAIPORT-powered Workstation , which can fulfill orders at in-bound and out-bound, involves collaboration between HAIPICK robots, HAIPORT and conveyor belts. HAIPORT is an automatic loading and unloading machine that can be docked with ACR robots and conveyor belts. At a HAIPORT-powered Workstation, multiple loads of totes or cartons are unloaded from the HAIPICK robots at the entry side of the HAIPORT, then transferred onto the conveyor belts for sorting per system orders and moved to the exit side of the HAIPORT, where they were fetched by robots for the next round of order processing.

The HAIPORT-powered Workstation is suitable for medium-to-large warehouses that have high throughput requirement of at least 400 bins per hour. It's machine rate can deliver 600 bins per hour to an operator. It suits for extensive storage scenarios in which medium and small-sized bins are used, such as raw materials, small electronics, apparel, medicine, retails and 3PL industries that have large number of SKUs.

ABOUT HAI ROBOTICS

HAI ROBOTICS, a trailblazer of Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse. The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.

Founded in 2016 in Shenzhen, China, HAI ROBOTICS has offices in the U.S., Europe, Japan, Southeast Asia, Hong Kong and Taiwan, serving customers from more than 30 countries and regions.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye